Catalogo dei prodotti della ricerca

CASATO, Milvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.709
EU - Europa 1.040
AS - Asia 630
SA - Sud America 37
AF - Africa 31
OC - Oceania 6
Totale 5.453
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.675
IT - Italia 355
SG - Singapore 314
SE - Svezia 231
IN - India 157
UA - Ucraina 125
CN - Cina 122
FI - Finlandia 92
DE - Germania 54
GB - Regno Unito 48
BG - Bulgaria 40
AR - Argentina 33
CA - Canada 27
TG - Togo 21
RO - Romania 19
IE - Irlanda 16
RU - Federazione Russa 14
TR - Turchia 12
ID - Indonesia 11
NL - Olanda 11
BE - Belgio 10
ZA - Sudafrica 6
AU - Australia 5
FR - Francia 5
PL - Polonia 5
CH - Svizzera 4
IR - Iran 4
EG - Egitto 3
HK - Hong Kong 3
MX - Messico 3
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
JP - Giappone 2
LT - Lituania 2
MY - Malesia 2
AZ - Azerbaigian 1
BZ - Belize 1
ES - Italia 1
GP - Guadalupe 1
LU - Lussemburgo 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
Totale 5.453
Salva come PNG Salva come JPEG
Città #
Fairfield 612
Chandler 325
Woodbridge 301
Ashburn 290
Singapore 247
Houston 232
Seattle 214
Wilmington 201
Cambridge 178
Ann Arbor 155
Rome 147
Princeton 107
Santa Clara 85
Beijing 81
Plano 77
San Paolo di Civitate 55
Lawrence 54
Boston 51
Dearborn 48
Jacksonville 45
San Diego 45
Sofia 40
Millbury 36
Andover 33
Federal 28
Des Moines 27
Boardman 24
New York 22
Lomé 21
Falls Church 18
Toronto 17
Dublin 16
Helsinki 16
Norwalk 14
Los Angeles 13
Milan 12
Bremen 11
Istanbul 11
Jakarta 11
Brussels 10
Bühl 10
Fremont 9
San Mateo 8
Southend 8
Falkenstein 7
Moscow 7
Bari 6
Fiuggi 6
Hefei 6
Lappeenranta 6
Mannheim 6
Nanjing 6
Ottawa 6
Auburn Hills 5
Buenos Aires 5
Pune 5
Dallas 4
London 4
Muizenberg 4
North Vancouver 4
Sydney 4
Cairo 3
Frankfurt am Main 3
Gavello 3
Gelsenkirchen 3
Munich 3
Padova 3
Redwood City 3
Venice 3
Venosa 3
Verona 3
Warsaw 3
Athens 2
Avigliano 2
Bucharest 2
Campobasso 2
Chicago 2
Chongqing 2
Crotone 2
Fuzhou 2
Gioia Tauro 2
Hong Kong 2
Hounslow 2
Jinan 2
Kunming 2
Latina 2
Lugano 2
Mexico City 2
Nanchang 2
Naples 2
Phoenix 2
Provo 2
Redmond 2
Rimini 2
Sacramento 2
San Giovanni Lupatoto 2
Silverton 2
Tappahannock 2
Velletri 2
Vicopisano 2
Totale 4.145
Salva come PNG Salva come JPEG
Nome #
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 102
The VH1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21low phenotype. 101
Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. 99
Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy 97
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 97
Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis 91
Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. 90
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 89
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 89
Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation 88
Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21 low cells overexpressing Stra13 86
The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy. 86
BETA-2-MICROGLOBULIN LEVELS IN SERUM AND IN SUPERNATANTS OF POKEWEED MITOGEN-STIMULATED PERIPHERAL-BLOOD MONONUCLEAR-CELLS IN PATIENTS AFFECTED WITH IDIOPATHIC MIXED CRYOGLOBULINEMIA 84
International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement 84
Clinical, neurophysiological, and skin biopsy findings in peripheral neuropathy associated with hepatitis C virus-related cryoglobulinemia 81
HCV\HGV coinfection and cryoglobulinemia. 80
Clinical effects of cyclosporin in dermatomyositis 80
Persistence of a Large Population of Exhausted Monoclonal B cells in Mixed Cryoglobuliemia After the Eradication of Hepatitis C Virus Infection 79
DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells 79
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection 77
Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity 77
Central nervous system involvement in HCV-Cryoglobulinemia vasculitis : A Multicenter case-control study using MRI and neuropsychological tests. 77
High prevalence of gluten sensitivity in a cohort of patients with undifferentiated connective tissue disease. 76
From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? 75
Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. 74
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 74
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 74
Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy 71
Central nervous system involvement in HCV-cryoglobulinemia vasculitis: A multicenter case control study using MRI and neuropsychological tests. 71
Mixed cryoglobulinemia secondary to visceral leishmaniasis 71
HBV messing with the B-cell genome leads to DLBCL 71
Mechanisms of pain in distal symmetric polyneuropathy. A combined clinical and neurophysiological study 69
Occult hepatitis C virus infection in type II mixed cryoglobulinaemia 69
Expression of biomarkers of interferon type I in patients suffering from chronic diseases 67
Atteintes du système nerveux central au coursdes vascularites cryoglobulinémiques du virus C étude cas-témoins 66
Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia 66
Analysis of the dynamics of cryoaggregation by light-scattering spectrometry 65
CLINICAL EFFECTS OF INTERFERON IN PATIENTS WITH IDIOPATHIC MIXED CRYOGLOBULINEMIA 64
Persistence of pathogenic B cell clones and relapse of cryoglobulinemic vasculitis in HCV-cured patients 64
Different genomic imbalances in low- and high-grade HCV-related lymphomas 63
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 63
HCV\HGV coinfection and cryoglobulinemia 62
TREATMENT OF IDIOPATHIC MIXED CRYOGLOBULINEMIA WITH ALPHA-INTERFERON 62
Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody 62
Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer 62
Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: Evidence for a synergistic hematologic toxicity - Reply 60
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinemy 60
Clinical, neurophysiological and skin biopsy study of peripheral neuropathy related to cryoglobulinaemia 60
Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia 59
Hepatitis C virus drives the unconstrained monoclonal expansion V(H)1-69-expressing memory B cells in type II cryoglobulinemia: A model of infection-driven lymphomagenesis 59
CRYOGLOBULINEMIA AND ALPHA-INTERFERON 58
Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not restricted to patients with cryoglobulinemia 58
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 58
Efficacy of low-dose rituximab for mixed cryoglobulinemia 58
Regression of splenic lymphoma after treatment of hepatitis C virus infection 58
CD21 low B cells are predictive markers of new digital ulcers in systemic sclerosis 58
Mixed Cryoglobulinemia Syndrome Secondary to Hepatitis C Virus Infection 57
RESISTANCE TO RECOMBINANT ALPHA-INTERFERON THERAPY IN IDIOPATHIC MIXED CRYOGLOBULINEMIA - REINDUCTION OF REMISSION BY NATURAL ALPHA-INTERFERON BOTH IN ANTIBODY-POSITIVE AND ANTIBODY-NEGATIVE PATIENTS 56
Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia 55
HCV infection in a patient with Hyper IgM syndrome 54
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 54
Clinico-immunologic outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy 54
Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. 54
Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. 52
null 49
Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals 45
Cryoglobulinaemia and hepatitis C virus. 44
Influence of age and autoimmunity on liver disease in HCV-associated type II mixed cryoglobulinemia 44
Analysis of Hepatitis C virus hypervariable region 1 sequence in cryoglobulinemic patients and associate controls 41
Cryoglobulins: putative effectors of adaptive immune response 41
Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy Reply 40
Safety and effectiveness of biosimilar of Rituximab CT‐P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar) 39
Approccio terapeutico nelle crioglubulinemie: esperienza di plasma-exchange e gel piastrinico in due pazienti. 37
Treatment with cyclosporine and cyclophosphamide of SLE and immune vasculitides 37
Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: A multicenter case-control study using magnetic resonance imaging and neuropsychological tests 37
COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis 36
Interferon toxicity in hepatitis C virus-associated type II cryoglobulinemia 36
Rheumatoid factor-producing CD21low anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and non-infectious cryoglobulinaemias 36
CLINICAL EFFECTS OF CYCLOSPORINE IN DERMATOMYOSITIS 35
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 35
HEPATITIS C VIRUS AND NEPHROTIC SYNDROME 34
Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia 34
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 31
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 31
Myths, misconceptions and mixed cryoglobulinemia associated with HCV infection. 29
HCV-Associated Lymphomas 28
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 28
Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) 26
Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection 26
Nonrheumatoid IgM in human hepatitis C virus-associated type II cryoglobulinemia recognize mimotopes of the CD4-like LAG-3 protein 24
The Marginal Zone B Cells Clonally Expanded in Hepatitis C-Related Mixed Cryoglobulinemia Display the Functional and Molecular Signatures of Anergy Induced by Continual B Cell Receptor Signaling 23
Evaluation of the Benefit/Cost/Safety Profile of Low-dose Anti-CD20 Monoclonal Antibody (Rituximab) Treatment for Refractory Mixed Cryoglobulinemia 23
Genetic pathways in low-and high-grade HCV-related lymphomas are different 21
Correction to: management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) 20
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 16
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 16
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 16
Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis 13
Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature 11
Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C 10
Totale 5.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.919
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020752 0 0 0 0 0 131 147 126 136 118 47 47
2020/2021462 36 59 17 15 18 33 12 35 63 127 40 7
2021/2022964 43 47 84 37 117 32 23 124 74 87 115 181
2022/20231.106 212 222 77 120 111 119 29 46 115 6 30 19
2023/2024467 32 88 11 30 39 99 13 19 0 56 30 50
2024/2025523 49 180 59 81 76 78 0 0 0 0 0 0
Totale 5.663